Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle

被引：38
|
作者：
Patel, Harun M. [1 ]
Pawara, Rahul [1 ]
Ansari, Azim [1 ]
Noolvi, Malleshappa [2 ]
Surana, Sanjay [1 ]
机构：
[1] RC Patel Inst Pharmaceut Educ & Res, Dept Pharmaceut Chem, Shirpur 425405, Maharashtra, India
[2] Shree Dhanvantary Pharm Coll, Dept Pharmaceut Chem, Surat 3941110, Gujarat, India
来源：
BIOORGANIC & MEDICINAL CHEMISTRY | 2017年 / 25卷 / 10期
关键词：
Quinazoline; Non Small Cell Lung Cancer; T790M EGFR; CELL LUNG-CANCER; GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; PAN-ERBB INHIBITOR; PHASE-II TRIAL; ACQUIRED-RESISTANCE; T790M MUTATION; IRREVERSIBLE INHIBITORS; ACCURATE DOCKING; GEFITINIB;
D O I：
10.1016/j.bmc.2017.03.039
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The epidermal growth factor receptor (EGFR) T790M mutant is found in about 50% of clinically acquired resistance to gefitinib among patients with non-small cell lung cancer (NSCLC). New derivatives of 4(3H)-quinazolinones were synthesized and evaluated for their inhibitory activity against NSCLC. The results of the study demonstrated that compound 79, 7-chloro-3-(5-(4-methoxypheny1)-1,3,4-thiadiazol-2-y1)-2-phenylquinazolin-4(3H)-one was found to be the most potent compounds of the series with IC50 value of 0.031 mu M against mutant T790M/L858R EGFR. Compounds 15, 51, 73, 75, 78, 79 and 96 were less potent against A549 (WT EGFR and k-Ras mutation) and HT-29 (non-special gene type) cells, showing a high safety index. The obtained results showed that compounds 15, 51, 73, 75, 78, 79 and 96 could be the promising template to overcome drug resistance mediated by the EGFR T790 Mutant. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码：2713 / 2723
页数：11
相关论文
共 50 条
  • [41] Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update
    Ahsan, Aarif
    LUNG CANCER AND PERSONALIZED MEDICINE: CURRENT KNOWLEDGE AND THERAPIES, 2016, 893 : 137 - 153
  • [42] AXL and acquired resistance to EGFR inhibitors
    Postel-Vinay, Sophie
    Ashworth, Alan
    NATURE GENETICS, 2012, 44 (08) : 835 - 836
  • [43] Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles
    Hossam, Monia
    Lasheen, Deena S.
    Abouzid, Khaled A. M.
    ARCHIV DER PHARMAZIE, 2016, 349 (08) : 573 - 593
  • [44] The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC
    Li, Shiyu
    Zhu, Shuangli
    Wei, Hongqu
    Zhu, Pengfei
    Jiao, Ying
    Yi, Ming
    Gong, Juejun
    Zheng, Kun
    Zhang, Li
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 156
  • [45] Signaling mechanisms of resistance to EGFR- and Anti-Angiogenic Inhibitors cancer
    Mirone, Giovanna
    Shukla, Arvind
    Marfe, Gabriella
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 97 : 85 - 95
  • [46] Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors
    Hou, Weijie
    Ren, Yan
    Zhang, Zhenhua
    Sun, Huan
    Ma, Yongfen
    Yan, Bo
    BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (08) : 1740 - 1750
  • [47] Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives
    Tomasello, Chiara
    Baldessari, Cinzia
    Napolitano, Martina
    Orsi, Giulia
    Grizzi, Giulia
    Bertolini, Federica
    Barbieri, Fausto
    Cascinu, Stefano
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 123 : 149 - 161
  • [48] Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
    Gazdar, A. F.
    ONCOGENE, 2009, 28 : S24 - S31
  • [49] Stressing the need to overcome EGFR tyrosine kinase inhibitor resistance
    Toulabi, Leila
    Ryan, Brid M.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S123 - S126
  • [50] Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors
    Ercan, Dalia
    Xu, Chunxiao
    Yanagita, Masahiko
    Monast, Calixte S.
    Pratilas, Christine A.
    Montero, Joan
    Butaney, Mohit
    Shimamura, Takeshi
    Sholl, Lynette
    Ivanova, Elena V.
    Tadi, Madhavi
    Rogers, Andrew
    Repellin, Claire
    Capelletti, Marzia
    Maertens, Ophelia
    Goetz, Eva M.
    Letai, Anthony
    Garraway, Levi A.
    Lazzara, Matthew J.
    Rosen, Neal
    Gray, Nathanael S.
    Wong, Kwok-Kin
    Jaenne, Pasi A.
    CANCER DISCOVERY, 2012, 2 (10) : 934 - 947
12345